Cargando…
Updates of incretin‐related drugs for the treatment of type 2 diabetes
Mechanisms of dipeptidyl peptidase‐4 inhibitors, glucagon‐like peptide‐1 receptor agonists and glucagon‐like peptide‐1 receptor/glucose‐dependent insulinotropic polypeptide receptor dual‐agonist in glycemic control and/or weight loss.[Image: see text]
Autores principales: | Araki, Hirotaka, Matsumura, Takeshi, Furukawa, Noboru, Araki, Eiichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9889679/ https://www.ncbi.nlm.nih.gov/pubmed/36373430 http://dx.doi.org/10.1111/jdi.13945 |
Ejemplares similares
-
New prospects for incretin‐related drugs in the treatment of type 2 diabetes
por: Kimura, Tomohiko, et al.
Publicado: (2020) -
New perspectives on insulin therapy
por: Araki, Eiichi, et al.
Publicado: (2020) -
Impacts of tight multifactorial intervention in patients with type 2 diabetes: Implications from the Japan Diabetes Outcome Intervention Trial 3
por: Araki, Eiichi, et al.
Publicado: (2018) -
Update information on type 1 diabetes in children/adolescents and adults
por: Miura, Junnosuke, et al.
Publicado: (2023) -
Updates on dyslipidemia in patients with diabetes
por: Ide, Shintaro, et al.
Publicado: (2023)